NASDAQ:MYNZ - Nasdaq - NL0015000LC2 - Common Stock - Currency: USD
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention...
Mainz Biomed Expands into Switzerland with labor team w...
Partnership to Launch DNA-Based Colorectal Cancer Screening Test
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering ...
Mainz Biomed Announces Stock Split...
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month...
Updated Screening Guidelines Ensure Broader Access to Colorectal Cancer Screening in Germany
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements...
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population...
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test...
Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval
Mentions: DGX
Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules...
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update...
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version; GANZIMMUN Diagnostics to Feature ColoAlert ...
GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025...
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador...
Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection